(Press-News.org) Only 1 in 4 residential addiction treatment facilities caring for U.S. adolescents under 18 years old offer buprenorphine, a medication used to treat opioid use disorder, according to a new study. Only 1 in 8 offer buprenorphine for ongoing treatment. These findings highlight a significant gap in access to evidence-based addiction treatment among young people. Published in JAMA, this study was supported by the National Institute on Drug Abuse (NIDA) and the National Center for Advancing Translational Sciences (NCATS), both part of the National Institutes of Health, and led by researchers at Oregon Health & Science University (OHSU).
There has been a dramatic rise in overdose deaths among young people aged 14-18 in recent years, likely driven by illicit counterfeit pills containing fentanyl. For those with opioid use disorder, medications are the most effective treatment options for preventing both return to opioid use and overdose deaths. Buprenorphine is the only medication for opioid use disorder that is approved by the U.S. Food and Drug Administration for use in people aged 16-18. Although buprenorphine is not approved for use among people under the age of 16 in the U.S., some professional medical societies recommend that buprenorphine be considered as a treatment option for opioid use disorder in younger people.
“It is tragic to see that young people with opioid use disorder are unable to access buprenorphine in most treatment facilities, despite this medication being the standard of care for people aged 16 and older” said Nora Volkow, M.D., director of NIDA. “Residential treatment facilities provide an opportunity to reach young people with a range of evidence-based supports at a pivotal time in their lives, and it is crucial that buprenorphine is made available as one of those options.”
Residential treatment facilities are part of the continuum of care for adolescents with opioid use disorder. However, little is known about specific evidence-based treatment options offered to young people at these facilities, including medications for opioid use disorder. To address this gap, researchers at OHSU sought to determine how many adolescent treatment centers in the U.S. were offering buprenorphine to treat opioid use disorder.
Using the FindTreatment.gov database, which is maintained by the Substance Abuse and Mental Health Services Administration (SAMSHA), the researchers identified a list of 354 centers across the U.S. that offered treatment for “substance use,” in a “residential/24-hour residential” service setting, and for “children/adolescents” (defined as people aged 17 and younger) to include in the analysis.
Researchers called these facilities to inquire about treatment and services offered as potential users of these services for a 16-year-old with a recent non-fatal fentanyl overdose. Between October and December 2022, the study team called the facilities in a random order and confirmed that 160 (45%) of these facilities provided residential treatment to patients under the age of 18.
Of the 160 residential addiction treatment facilities found to provide treatment to young patients, the researchers found that 39 facilities (24%) said that they offered buprenorphine to patients aged 16 or older, including through partnership with outside prescribing clinicians, though specific parameters for offering buprenorphine varied by site. For instance, only 20 facilities (12.5%) said that they offered buprenorphine for ongoing treatment. 12 facilities (7.5%) said that they offered buprenorphine to adolescents under 16 years of age.
Among the other 121 facilities that did not offer buprenorphine to adolescents or weren’t sure, 57 (47%) indicated that adolescents prescribed buprenorphine by their own clinician could stay on it at least temporarily, although some stated they would discontinue it before discharge. And 27 (22%) required that adolescents were not taking buprenorphine in order to be admitted for residential treatment.
Based on these findings, the average person would need to call nine facilities on the SAMHSA list to find one that offered buprenorphine. To find one for an adolescent under 16, they would need to call 29 facilities.
“These residential treatment centers see some of the most vulnerable adolescents in our communities,” said lead author Caroline King, M.D., Ph.D., who completed this research as a student in the OHSU School of Medicine. “We need to support these centers to make evidence-based care the norm.”
“Buprenorphine is the one medication that’s approved for use in adolescents, and it’s underused in facilities taking care of kids with the most severe opioid use disorder,” said co-author Todd Korthuis, M.D., M.P.H., head of addiction medicine at OHSU. “It’s a big issue, but it’s something that we can change by supporting these treatment centers with education and technical assistance about buprenorphine, better funding to staff these centers, and by letting the public know that buprenorphine is necessary treatment in healing brains.”
For more information on substance and mental health treatment programs in your area, call the free and confidential National Helpline 1-800-662-HELP (4357) or visit www.FindTreatment.gov.
Reference: C King, et al. Treatments used among adolescent residential addiction treatment facilities in the United States, 2022. JAMA. DOI: 10.1001/jama.2023.6266 (2023).
###
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
END
LA JOLLA (June 13, 2023)—The immune system protects the body from invaders, such as bacteria, viruses, or tumors, with its intricate network of proteins, cells, and organs. Specialized immune cells, called cytotoxic T cells, can develop into short-lived effector cells that kill infected or cancerous cells within our bodies. A small portion of those effector cells remain after an infection and become longer-lived memory cells, which “remember” infections and respond when infections reappear. ...
PHILADELPHIA—The Pew Charitable Trusts today announced the 22 researchers selected to join the Pew Scholars Program in the Biomedical Sciences. These early-career scientists will receive four years of funding to spearhead innovative studies exploring human health and medicine.
“From vaccine development to treatments for complex diseases, biomedical research is foundational to solving some of the world’s greatest health challenges,” said Susan K. Urahn, Pew’s president and CEO. “Pew is thrilled to welcome this new class of researchers and support their efforts to advance scientific knowledge and improve human ...
PHILADEPHIA—The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2023 class of the Pew-Stewart Scholars Program for Cancer Research.
These early-career scientists will receive four-year grants to explore new horizons in cancer development, diagnosis, and treatment. This class marks the 10th year the Alexander and Margaret Stewart Trust has partnered with Pew to build a legacy of innovative cancer research.
“Cancer is one of the most pressing challenges facing biomedical researchers today,” said Susan K. Urahn, Pew’s president and CEO. “Pew ...
PHILADELPHIA – The Pew Charitable Trusts today announced the 2023 class members of the Pew Latin American Fellows Program in the Biomedical Sciences.
These 10 postdoctoral fellows from seven Latin American countries—Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Uruguay—will receive two years of funding to conduct research in laboratories throughout the United States. The fellows will work under the mentorship of prominent biomedical scientists, including an alum of the Pew Scholars Program in the Biomedical Sciences.
“Scientific ...
Most women diagnosed with early stage breast cancer today can expect to become long term cancer survivors, finds a study published by The BMJ today.
The findings show that the average risk of dying from breast cancer in the five years after a diagnosis has fallen from 14% to 5% since the 1990s. For those diagnosed during 2010-15, more than six in 10 women had a five year risk of 3% or less.
The researchers say their findings can be used to reassure most women treated for early breast cancer that they are likely to become long term cancer survivors. ...
The American College of Medical Genetics and Genomics (ACMG) has released updated recommendations for CFTR carrier screening –Updated recommendations for CFTR carrier screening: A position statement of the American College of Medical Genetics and Genomics. Pathogenic variants in the CFTR gene can cause cystic fibrosis (CF) as well as CF-related disorders. The new updated ACMG CFTR variant list includes a set of 100 variants.*
The new CFTR variant list represents an updated minimum recommended variant set for CF carrier screening and supersedes the previous group of 23 CFTR variants recommended by the ACMG. These revised recommendations apply to carrier screening, a type of genetic ...
OAK BROOK, Ill. – A common weight-loss surgery for obese adolescents and young adults is found to have harmful effects on bones, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).
“Childhood obesity is on the rise and weight-loss surgery is the most effective way to reduce weight and improve cardiometabolic comorbidities,” said the study’s lead investigator, Miriam A. Bredella, M.D., professor of radiology at Harvard Medical School in Boston, Massachusetts, and vice chair for Faculty Affairs and Clinical Operations, Department of Radiology ...
PeerJ, the award-winning Open Access publisher, has announced the launch of the Open Advances series of journals, part of its ongoing commitment to democratizing scientific communication. The series will foster an equitable approach that empowers researchers worldwide to contribute valuable insights towards solving global challenges. The journals will be fully Open Access but will not charge authors a fee to publish.
The Open Advances series is a transformative endeavor that cements PeerJ's commitment to openness, innovation, ...
June 13, 2023 – Enrollment in the Medicare Advantage program – which allows Medicare beneficiaries to get their health care through plans administered by private insurance companies – has been growing so rapidly that it has recently surpassed enrollment in traditional Medicare. A new analysis by USC researchers warns that overpayments to Medicare Advantage plans now exceed 20 percent or $75 billion annually, underscoring the urgent need for reform.
Researchers with the USC Schaeffer Center for Health Policy & Economics found that the millions of beneficiaries in traditional Medicare who have switched to Medicare ...
Philadelphia, June 13, 2023 – Cognitive deficits accompany mood disorders and other psychiatric conditions, often with debilitating effects. Limited treatments currently exist, but studies in animals and humans have pointed to drugs such as the laxative prucalopride that activate serotonin receptors as a potential therapeutic for the symptoms. It has remained unclear, however, how the medication affects resting brain activity. Now, a new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier, examines the drug’s effects in healthy human adults.
Serotonin receptors and the 5-HT4-type receptors in particular are found in areas ...
